Swine and Avian Influenza Drug Development Pipeline Review, 2017

Thursday, March 1, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 1, 2018 /PRNewswire/ -- Swine and Avian Influenza Drug Development Pipeline Review, 2017SummaryRead

the full report: https://www.reportlinker.com/p05236703 H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. There are a total of 63 products
in development for this indication, by 47 companies and six academic institutions. Key companies operating in this pipeline space include Gemmus Pharma, Aphios, Fides Pharma, Inovio Pharmaceuticals, Microbiotix, NanoViricides, Shionogi, the University of Wisconsin Madison and Tria Bioscience.H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by the contagious H1N1 influenza virus. There are a total of 99 products in development for this indication, by 67 companies and 14 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, and the University of Sherbrooke.In both types of influenza, the most common molecular target being studied is hemagglutinin, by a considerable margin. However, a number of both human and viral proteins are also under active development.This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects. Symptoms of influenza include fever and cough, fatigue, acute respiratory distress, shortness of breath, abdominal pain and diarrhea.Scope- Which companies are the most active within each pipeline?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in this disease area?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05236703 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/swine-and-avian-influenza-drug-development-pipeline-review-2017-300606767.html

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store